AUTHORS
Mackenzie Emily Lemieux, MD, Hira Mian, MD2, Ghulam Rehman Mohyuddin, MD3, Hsien Seow4, Alissa Visram, MD, MPH5, Gregory Pond, PhD6
AFFILIATIONS
1 University of Utah Huntsman Center, Salt Lake City, United States
2 McMaster University, Hamilton, Ontario, Canada
3 University of Utah Huntsman Center, Salt Lake City, United States
4 McMaster University, Hamilton, Ontario, Canada
5 McMaster University, Hamilton, Ontario, Canada
6 McMaster University, Hamilton, Ontario, Canada
ABSTRACT
Background: Lenalidomide maintenance therapy after autologous stem cell transplant (ASCT) is a cornerstone of contemporary myeloma management (Palumbo 2012; Callander 2022; Amsler 2019). Clinical guidelines generally recommend continuous therapy until progression, though this may not reflect the comorbidity burden and treatment tolerance of routine practice. Recent data from the ENDURANCE randomized trial showed overall survival was not superior with indefinite maintenance compared to 2 years of maintenance, but this trial was done in a transplant deferred setting (Kumar, 2026). In clinical practice, patients may discontinue lenalidomide before disease progression for various reasons, and population-based data characterizing real-world lenalidomide maintenance patterns remain sparse (Derman, 2025). Here, we characterize real-world maintenance duration, discontinuation, and survival patterns in a large, population-based cohort of myeloma patients receiving lenalidomide maintenance after ASCT in Ontario, Canada.
Methods: Using administrative data at ICES, we used the Ontario Cancer Registry to identify individuals diagnosed with myeloma between 2008-2024 who underwent ASCT within 1 year of diagnosis (n=4,704). Among them, individuals who initiated lenalidomide maintenance (with or without additional maintenance therapies) within 6 months of ASCT (n=2,299) were included by linking with the Ontario Drug Benefit and Cancer Activity Level Reporting databases. Baseline demographics, induction/maintenance regimens, and lenalidomide duration were recorded. Time to treatment failure (initiation of second line regimen (proxy for progressive disease), discontinuation of lenalidomide without starting next line regimen (proxy for stopping treatment without progressive disease) or death on treatment) was summarized descriptively (n [%], median [IQR]) by outcome type; overall survival (OS) and follow-up were estimated using Kaplan-Meier methods.
Results: Median age at lenalidomide start was 63 years (Q1-Q3, 57-68); 58.1% (n=1,335) were male. Median time from ASCT to lenalidomide initiation was 104 days (Q1-Q3, 90-130). Of 2,299 patients, 1,988 (86.5%) underwent a single ASCT and 311 (13.5%) underwent tandem ASCTs. Most patients initiated maintenance after 2015 (96.7%), consistent with lenalidomide's 2014 approval for maintenance in Ontario. Induction pre-ASCT most commonly included bortezomib (98.2%, n=2,258) and cyclophosphamide (90.1%, n=2,072), consistent with commonly used regimens of CYBORD in the province, while only 20.4% (n=468) included lenalidomide. A minority received dual maintenance with bortezomib (21.0%, n=482) or daratumumab (3.2%, n=74) in addition to lenalidomide. With a median follow-up of 4.95 years, median OS for the cohort was 9.47 years (95% CI, 8.29-not reached). During follow-up, 1,061 patients (46.2%) started a second line regimen, at a median of 22.2 months (Q1-Q3, 8.7-41.5) after lenalidomide initiation. Of the remainder, 274 (11.9%) discontinued lenalidomide with no subsequent therapy recorded, after a median of 24.4 months (Q1-Q3, 8.2-45.0) on maintenance. A total of 808 (35.2%) remained on lenalidomide at last follow-up, with a median maintenance duration of 34.1 months (Q1-Q3, 15.4-65.2); and 156 (6.8%) died while on maintenance, after a median of 20.0 months (Q1-Q3, 6.3-41.6).
Conclusions: In this large, population-based cohort, real-world lenalidomide maintenance duration was highly heterogeneous. By studying a real-world setting in which lenalidomide is publicly funded, we remove the confound of financial barriers to treatment. Despite this, greater than one tenth of patients stop treatment, for reasons likely related to intolerance, and nearly half of patients required a new therapy within two years. While over a third of patients remained on treatment through last follow-up, real-world maintenance duration is markedly shorter and more variable than reported in clinical trials. Median OS (9.47 years) far exceeded time to new therapy (~22 months), suggesting substantial post-relapse survival with modern salvage therapy. These findings may inform future prospective studies, including trials of fixed-duration maintenance strategies, and will be directly relevant to clinicians, researchers, and policymakers seeking to optimize maintenance therapy for myeloma.
DISCLOSURES
Mackenzie Emily Lemieux, MD: No relevant conflicts of interest to declare.